Fig. 2.

Mean change in visual acuity from baseline to Year 1 by (A) injection frequency, (B) loading and nonloading dose, and (C) baseline visual acuity. Observed data set (primary treated eye set). Values in parentheses represent the Snellen visual acuity equivalent. *Total number of patients at enrollment from global cohort. †Total number of patients with baseline and Year 1 data from global cohort. ‡Number of evaluable patients with baseline and Year 1 data based on injection frequency category. **Number of evaluable patients with baseline and Year 1 data for 6 to 9 injection stratum. #Final visual acuity at Year 1. $Number of evaluable patients with baseline and Year 1 data based on the baseline visual acuity. Loading dose group is defined as the patients who received the three initial consecutive monthly ranibizumab injections up to Day 100. For treatment-naive eyes, the date of first on-study injection with ranibizumab was considered the baseline date. For the 1-year period, all patients with nonmissing baseline visual acuity and Year 1 visual acuity performed anywhere between Day 319 and Day 409 but who had been in the study for at least 365 days from baseline to the last follow-up date were included in the analysis. ETDRS, Early Treatment Diabetic Retinopathy Study.